National Heart Foundation of Australia consensus statement on catheter ablation as a therapy for atrial fibrillation

Jonathan M Kalman, Prashanthan Sanders, David B Brieger, Anu Aggarwal, Nick A Zwar, James Tatoulis, Andre E Tay, Alison Wilson and Maree G Branagan
Med J Aust 2013; 198 (1): 27-28. || doi: 10.5694/mja12.10929


  • Jonathan M Kalman1
  • Prashanthan Sanders2
  • David B Brieger3
  • Anu Aggarwal1
  • Nick A Zwar4
  • James Tatoulis5
  • Andre E Tay6
  • Alison Wilson5
  • Maree G Branagan5

  • 1 Department of Cardiology, Royal Melbourne Hospital, Melbourne, VIC.
  • 2 Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, SA.
  • 3 Department of Cardiology, Concord Hospital, Sydney, NSW.
  • 4 School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW.
  • 5 National Heart Foundation of Australia, Melbourne, VIC.
  • 6 St Vincent’s Hospital, Sydney, NSW.



Funding and coordination was provided by the National Heart Foundation of Australia. Expert members contributed to the technical content on an honorary basis. Prashanthan Sanders is funded by the National Heart Foundation of Australia. The CSANZ was consulted in the development of this document and has endorsed the content.

Competing interests:

Jonathan Kalman has received funding for consultancy, advisory work and travel, and for investigator-initiated research, from Medtronic and St. Jude Medical.

Prashanthan Sanders has received money paid to his institution for board membership from St. Jude Medical, Medtronic, Bard Electrophysiology, Sanofi, MSD, and Biosense Webster; grants paid to his institution from Biosense Webster, St. Jude Medical and Sanofi; payment for lectures from St. Jude Medical, MSD, Biosense Webster and Bard Electrophysiology; and financial assistance with travel expenses paid to his institution from Boehringer Ingelheim, St. Jude Medical, Medtronic and Biosense Webster.

Nick Zwar was the chief investigator in an NHMRC project grant, examining stroke prevention in patients with AF. A grant was paid to his institution by the NHMRC. New therapies for treating AF were not being used in this project.

Alison Wilson received travel assistance from Sanofi.

  • 1. Camm AJ, Kirchhof P, Lip GY, et al; European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
  • 2. PricewaterhouseCoopers.The economic costs of atrial fibrillation in Australia. June 2010. (accessed Oct 2012).
  • 3. Wong CX, Brooks AG, Leong DP, et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med 2012; 172: 739-741.
  • 4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
  • 5. National Health and Medical Research Council. NHMRC levels of evidence and grades for recommendations for developers of clinical practice guidelines. Canberra: NHMRC, 2009. (accessed Aug 2012).
  • 6. Calkins H, Brugada J, Packer DL, et al; European Heart Rhythm Association (EHRA); European Cardiac Arrhythmia Scoiety (ECAS); American College of Cardiology (ACC); American Heart Association (AHA); Society of Thoracic Surgeons (STS). HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4: 816-861.
  • 7. Oral H, Chugh A, Ozaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114: 759-765.
  • 8. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010; 55: 735-743.
  • 9. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666.
  • 10. Haïssaguerre M, Shah D, Jaïs P, et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000; 102: 2463-2465.
  • 11. Brooks AG, Stiles MK, Laborderie J, et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm 2010; 7: 835-846.
  • 12. Brooks AG, Wilson L, Kuklik P, et al. Image integration using NavX Fusion: initial experience and validation. Heart Rhythm 2008; 5: 526-535.
  • 13. Natale A, Raviele A, Arentz T, et al. Venice Chart international consensus document on atrial fibrillation ablation. J Cardiovasc Electrophysiol 2007; 18: 560-580.
  • 14. Kobza R, Hindricks G, Tanner H, et al. Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, mechanisms, and treatment. Heart Rhythm 2004; 1: 676-683.
  • 15. Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008; 118: 2498-2505.
  • 16. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006; 48: 2340-2347.
  • 17. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634-2640.
  • 18. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303: 333-340.
  • 19. Medi C, Sparks PB, Morton JB, et al. Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up. J Cardiovasc Electrophysiol 2011; 22: 137-141.
  • 20. Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010; 122: 2368-2377.
  • 21. Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011; 57: 160-166.
  • 22. Lee G, Sparks PB, Morton JB, et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol 2011; 22: 163-168.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.